A8 Chemotherapy

Topic

Chemotherapy employs cytotoxic agents that interfere with DNA replication or cell division, thereby preferentially affecting rapidly proliferating cells. While this characteristic allows for targeting tumor cells, it also damages healthy, high-turnover tissues—particularly the bone marrow, mucous membranes, and hair follicles.

A single dose of chemotherapy does not eliminate a fixed number of tumor cells but rather a specific fraction of the existing ones. If a treatment destroys 99% of the cells, approximately 1% survive, regardless of the initial count. Consequently, multiple cycles are required: each cycle eliminates a fraction of the remaining cells, and successive repetitions allow the tumor population to be reduced to extremely low levels.

Efficacy also depends on the proportion of cells actively dividing. Since cytotoxic agents act primarily on proliferating cells, their effect is greater when this fraction is high. This principle helps justify the use of chemotherapy prior to surgery for certain tumors, as well as regimens involving more frequent cycles, which limit the time available for surviving cells to resume proliferation between treatments.

Among the healthy tissues affected, the bone marrow presents one of the primary limitations. Each cycle can temporarily suppress the progenitor cells responsible for producing neutrophils. Consequently, neutrophil counts in the blood progressively decline after treatment, reaching a nadir approximately one or two weeks later before recovering as the bone marrow restores production. If the neutrophil count drops below a critical level and fever develops, febrile neutropenia occurs—an oncological emergency due to the high risk of bacterial infection. Medications that stimulate neutrophil production in the bone marrow can be administered to accelerate recovery.

Another fundamental issue is resistance. Each division of a tumor cell carries a small probability that a mutation conferring resistance to a specific drug will arise. Although this individual probability is very low, in a tumor composed of a vast number of cells, the likelihood that a resistant cell already exists prior to the start of treatment increases significantly. By eliminating sensitive cells, chemotherapy can leave behind a surviving population enriched with resistant cells.

Combining several agents with different mechanisms of action reduces this possibility. To survive combination therapy, a cell would need to possess resistance mechanisms against all the drugs used simultaneously—a scenario far less likely than being resistant to just one. This principle explains the common use of multi-drug chemotherapy regimens.

Furthermore, the treatment involves a narrow margin between the dose capable of effectively destroying tumor cells and the dose that causes significant toxicity in healthy tissues. Consequently, the dosage must be carefully tailored to each patient. Factors such as weight, body surface area, and renal and hepatic function are taken into account; in certain cases, direct measurement of drug exposure in the blood is used to adjust the treatment.

Overall, chemotherapy relies on balancing anti-tumor efficacy against toxicity. Successive cycles aim to progressively reduce the tumor population by repeatedly destroying a fraction of its cells; treatment frequency and timing are designed to capitalize on periods of peak cell proliferation; monitoring neutrophil levels allows for the detection and management of bone marrow toxicity; and drug combinations reduce the risk of resistance. At the same time, the narrow margin between efficacy and toxicity necessitates careful individualization of dosages. Thus, the treatment is adjusted cycle by cycle to maximize tumor destruction while preserving the body's capacity to recover and maintain its defense functions.

ID:2271